

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Andexanet alfa for reversing anticoagulation

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Portola Pharmaceuticals (andexanet alfa) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Anticoagulation UK • Atrial Fibrillation Association • Black Health Agency • British Cardiac Patients Association • British Lung Foundation • Cardiovascular Care Partnership UK • Circulation Foundation • Different Strokes • Heart UK • Pumping Marvellous Foundation • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Surgeons of Great Britain and Ireland • British Association for Accident and Emergency Medicine • British Association for Immediate Care • British Cardiovascular Society • British Geriatrics Society • British Trauma Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society • Clinical Leaders of Thrombosis 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AAH Pharmaceuticals (tranexamic acid) • Accord Healthcare (tranexamic acid) • AMCo (tranexamic acid) • Baxalta UK (prothrombin complex concentrate) • Bowmed Ibisqus (tranexamic acid) • Focus Pharmaceuticals (tranexamic acid) • Octapharma, (prothrombin complex concentrate) • Pfizer (tranexamic acid)

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • College of Paramedics • Royal College of Anaesthetists • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal Pharmaceutical Society • Royal College of Physicians • Royal College of Surgeons • Royal Society of Medicine • Society of Cardiothoracic Surgeons • St Johns Ambulance • The Intensive Care Society • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Hounslow CCG • NHS Sutton CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Thrombosis Research Institute • Trauma Audit Research Network • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.